Presence of Tumour and Higher Levels of LAG3-positive T-cells in the Blood May Be Necessary to Derive Clinical Benefit with Nivolumab Plus Relatlimab Over Nivolumab in Melanoma By Ogkologos - November 11, 2025 282 0 Facebook Twitter Google+ Pinterest WhatsApp Primary results of RELATIVITY-098 and translational evidence from RELATIVITY-098 and RELATIVITY-047 studies Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Encorafenib, Cetuximab Combination Approved for Metastatic Colorectal Cancer May 8, 2020 Embedding research integrity at the core of our science July 28, 2021 FDA Approves Engineered Cell Therapy for Advanced Synovial Sarcoma August 27, 2024 Lorlatinib in First-Line Treatment of Patients with Advanced ALK-Positive NSCLC With... May 30, 2022 Load more HOT NEWS Body Location May Influence Fate of Cells with Cancer-Causing Mutations What to Know About Returning to Work After Cancer Treatment: An... How Financial Toxicity Can Impact Cancer Caregivers and Where to Find... Telehealth Can Save People with Cancer Time, Travel, and Money
